Zacks Investment Research lowered shares of Marrone Bio Innovations Inc. (NASDAQ:MBII) from a hold rating to a sell rating in a research note published on Thursday.

According to Zacks, “Marrone Bio Innovations Inc. develops environmentally safe bio-based products. The Company specializes in the discovery, development, and marketing of natural products for weed, pest, water resource, and plant disease management. It offers crop protection products for conventional and organic crop production, including herbicides for weed control, fungicides for plant disease control, nematicides for parasitic roundworm control, insecticides for insect and mite killers and plant growth regulators that growers use to increase crop yields, enhance plant health, manage pest resistance, and reduce chemical residues. Marrone Bio Innovations Inc. is headquartered in Davis, California. “

Marrone Bio Innovations (NASDAQ:MBII) opened at 2.12 on Thursday. The company’s market cap is $52.23 million. The stock has a 50 day moving average price of $1.91 and a 200 day moving average price of $1.24. Marrone Bio Innovations has a one year low of $0.60 and a one year high of $2.79.

Marrone Bio Innovations (NASDAQ:MBII) last released its earnings results on Monday, November 14th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.07. Marrone Bio Innovations had a negative net margin of 258.51% and a negative return on equity of 2,083.14%. On average, equities analysts anticipate that Marrone Bio Innovations will post ($1.17) EPS for the current fiscal year.

A hedge fund recently bought a new stake in Marrone Bio Innovations stock. Ardsley Advisory Partners acquired a new stake in shares of Marrone Bio Innovations Inc. (NASDAQ:MBII) during the third quarter, according to its most recent 13F filing with the SEC. The firm acquired 774,438 shares of the company’s stock, valued at approximately $1,324,000. Ardsley Advisory Partners owned approximately 3.15% of Marrone Bio Innovations at the end of the most recent quarter. Institutional investors and hedge funds own 40.60% of the company’s stock.

About Marrone Bio Innovations

Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.

5 Day Chart for NASDAQ:MBII

Receive News & Stock Ratings for Marrone Bio Innovations Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations Inc. and related stocks with our FREE daily email newsletter.